“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

05 July 2019
Pharma

Visiongain has launched a new pharma report Global Influenza Vaccines Market Report : Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other.

Growth is mainly driven by the ageing population and the increasing prevalence of health problems associated with age. This will drive the demand from both the developing and the developed world for influenza vaccines. The emerging markets will benefit from improved healthcare systems and in turn they will add to the demand of the influenza vaccines owing to their high birth rates. Furthermore, research and development will lead to continuous innovation within the vaccines industry. Advancements will be made in the delivery and target technology used in the influenza vaccines.

The lead analyst of the report commented "The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market. There is an increasing focus to identify the research gaps and unmet needs of the influenza vaccines market. This includes vaccine technology that provides wider coverage and easier access and administration of the influenza vaccines. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create newer influenza vaccine technology that is not already on the market. This prevents stagnation within the market and will help drive the growth of the influenza vaccines market."

Leading companies featured in the report include Sanofi Pasteur, Seqirus, GlaxoSmithKline (GSK), AstraZeneca, Abbott Laboratories, Sinovac Biotech and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever